Funding will be necessary to validate your therapeutic compound candidate, as you take the protein-based molecule through target validation, lead identification, and optimization.

You will also need intellectual property (IP) protection. Researching and filing for patent protection – and understanding best practices to increase chances for success – is critical at this early stage.

With funding and patents in hand, your promising biologics candidate is ready for Pre-Clinical Testing.

The early stages

The first twelve months of your endeavor may be the most critical period to ensure the success of your therapeutic candidate. We provide resources that allow you to focus on discovering your innovation that may help patients in need.

You can spend more time on discovery by spending less time on procurement and management of supplies. Select bioscience materials to optimize your lab for what matters most to you and your investors. Get guidance on essential reagents, supplies and instruments critical to your workflow to ensure that your lab budget is under control.

Emerging Biotech: Stay Current

Advance Biotech Grant Program – Accelerating Therapeutic Development in Life Science

The Life Science business of MilliporeSigma is expanding its commitment to the global biotech community with its Advance Biotech Grant Program. Through the newly expanded grant program, every six months, three recipients around the globe will be awarded a total of €200,000 in free services and products to address their process development challenges. In total, six companies will benefit from the Advance Biotech Grant Program each year.
Press Release

Find out more about our programs:

Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.

WHITE PAPER: 2017 Life Science Executive Summit

The Changing Biopharma Risk Equation

A report from the The Economist Intelligence Unit sponsored by MilliporeSigma.This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.